Médecins Sans Frontières (MSF) welcomes the European Commission’s ambition to ensure access to affordable medical tools. Beyond evaluating and revising the pharmaceuticals legislation, the Commission should take a comprehensive approach to revising the EU’s intellectual property (IP) and research and development (R&D) legislation and policies to meet this ambition.
MDS
Médecins Sans Frontières
NGO · Switzerland · EU Transparency Register 928308827208-10
3
positions filed
in the 583 files tracked
3
legislative files
of 583 tracked
3
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 964 non-governmental organisations on this site, they rank #364 by legislative files engaged — a count of participation, not a measure of influence.
3
declared lobbying FTE
self-declared
—
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2017
in the register since
Declares membership of
- Médecins Sans Frontières International is not a member of any external association
- confederation
- or network.
- More information here: https://www.msf.org/how-we-are-run
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026).
- Register category
- Non-governmental organisations
- Registered as
- Médecins Sans Frontières International (MSF International)
- Head office
- Geneva, Switzerland
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Médecins in PolicySpeak: request access →
Work at Médecins Sans Frontières? so we know who speaks for it.
Their record over time
Médecins Sans Frontières filed 3 positions between 27 Apr 2021 and 29 Apr 2022, across 3 of the 583 legislative files tracked here, attaching a full position paper 3 times.
2021 · 1 filed2022 · 2 filed
What they argued
Médecins Sans Frontières/Doctors Without Borders (MSF) welcomes the European Commission (EC)’s ambition to improve compulsory licensing (CL) in the EU. The Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS Agreement) and the Doha Declaration recognise that WTO members are free to determine the grounds on which to issue a CL.
Médecins Sans Frontières (MSF) recently published research in a peer-reviewed journal (attached) on supplementary protection certificates and their impact on access to medicines in Europe.1 The study examines sales revenue of and R&D investments in a number of lifesaving medicines (sofosbuvir, trastuzumab, and imatinib).
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Médecins Sans Frontières next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Showing 5 of 43.
Is this your organization?
Everything on this page comes from Médecins Sans Frontières’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.